Piramal Pharma Limited Announces Results for Q2 and H1 FY27

Piramal Pharma’s Q2FY27 revenue rose 28% YoY to ₹2,617 crore and EBITDA increased 72% to ₹385 crore, with the EBITDA margin expanding to 14.7% from 11.0%. The company upgraded FY27 revenue-growth guidance to 19%–20%, citing first-half performance and continued momentum, although H1FY27 net profit after exceptional items remained a loss of ₹64 crore and net debt increased to ₹4,859 crore from ₹4,164 crore at March 31, 2026.

Analysis

The quality of the beat matters more than the growth headline: utilization-driven margin expansion can lift earnings quickly, but it is less durable if new orders fail to convert into repeat production. Customer wins and audits are leading indicators, not contracted revenue; the 28 October call should clarify backlog conversion, project mix and whether the higher margin is sustainable. The key counterweight is weak conversion below EBITDA: depreciation and interest absorb much of operating profit, while net debt rose alongside fixed and intangible assets. On a rough H1 annualized EBITDA basis, net debt is about 3.6x; that is a directional leverage check, not a covenant measure, and seasonality may distort it. Further investment without matching cash generation would make the equity more sensitive to execution slippage.

Near term, upgraded guidance and H2 seasonality may support sentiment, but the market could be over-crediting RFP activity as realized sales. Over 1–3 months, watch organic CDMO growth, segment margins, cash conversion and debt; over 6–18 months, sustained utilization and successful conversion of customer programs would validate operating leverage. CHG growth also merits separation of underlying demand from the contribution of the Kenalog integration and ex-US anesthesia sales. The article provides no valuation or market expectations, so there is no defensible price target or unconditional long. AbbVie’s mentioned Indian associate is not evidence of a material earnings catalyst for AbbVie Inc.

Key Decisions for Investors

• Do not chase the headline before the 28 October call. Treat Piramal Pharma as a conditional long/watch: add only if management supports the FY outlook with conversion visibility and cash generation, rather than relying on order-inflow commentary alone.
• For the next 1–3 months, track quarterly CDMO revenue and EBITDA margin alongside operating cash flow and net debt. Falsify the margin-recovery thesis if utilization-led gains reverse or debt continues rising without improving cash conversion.
• Avoid using ABBV as a proxy for this news: the article gives no quantified earnings contribution from its Indian associate, and no material ABBV impact is established.
• No valuation-based pair or options trade is warranted from the supplied information; reassess after the call and current price/consensus data are available.